Bionest

Report on ESMO 2018 – Part One

We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings,┬áplus plenty of positive data from a variety of combination therapy trials in breast cancer, including triple-negative breast cancer.   (Neo)Adjuvant Treatment Gets a Boost  ...